Department of Physiology, School of Medicine of Ribeirao Preto, University of Sao Paulo, Ribeirao Preto, Sao Paulo, Brazil.
Clin Exp Pharmacol Physiol. 2012 Feb;39(2):151-4. doi: 10.1111/j.1440-1681.2011.05658.x.
The present study provides the first in vivo evidence that the cannabinoid CB(1) receptor mediates the effects of dexamethasone on hormone release induced by changes in circulating volume and osmolality. Male adult rats were administered with the CB(1) receptor antagonist rimonabant (10 mg/Kg, p.o.), followed or not in 1 hour by dexamethasone (1 mg/Kg, i.p.). Extracellular volume expansion (EVE, 2 mL/100 g of body weight, i.v.) was performed 2 hours after dexamethasone or vehicle treatment using either isotonic (I-EVE, 0.15 mol/L) or hypertonic (H-EVE, 0.30 mol/L) NaCl solution. Five minutes after EVE, animals were decapitated and trunk blood was collected for all plasma measurements. Rimonabant potentiated oxytocin (OT) secretion induced by H-EVE and completely reversed the inhibitory effects of dexamethasone in response to the same stimulus. These data suggest that glucocorticoid modulation of OT release is mediated by the CB(1) receptor. Although dexamethasone did not affect vasopressin (AVP) secretion induced by H-EVE, the administration of rimonabant potentiated AVP release in response to the same stimulus, supporting the hypothesis that the CB(1) receptor regulates AVP secretion independently of glucocorticoid-mediated signalling. Dexamethasone alone did not affect atrial natriuretic peptide (ANP) release stimulated by I-EVE or H-EVE. However, pretreatment with rimonabant potentiated ANP secretion induced by H-EVE, suggesting a possible role for the CB(1) receptor in the control of peripheral factors that modulate cardiovascular function. Rimonabant also reversed the inhibitory effects of dexamethasone on H-EVE-induced corticosterone secretion, reinforcing the hypothesis that the CB(1) receptor may be involved in the negative feedback exerted by glucocorticoids on the activity of the hypothalamic-pituitary-adrenal axis. Collectively, the results of the present study indicate that the CB(1) receptor modulates neurohypophyseal hormone secretion and systemic factors, such as corticosterone and ANP, thus participating in homeostatic responses to altered extracellular volume and plasma tonicity.
本研究首次提供了体内证据,表明大麻素 CB(1) 受体介导了地塞米松对循环血量和渗透压变化引起的激素释放的影响。雄性成年大鼠给予大麻素 CB(1) 受体拮抗剂利莫那班(10mg/kg,po),1 小时后给予地塞米松(1mg/kg,ip)。地塞米松或载体处理后 2 小时,通过静脉内给予 2 毫升/100 克体重的等渗(I-EVE,0.15mol/L)或高渗(H-EVE,0.30mol/L)NaCl 溶液进行细胞外液扩张(EVE)。EVE 后 5 分钟,动物断头取血,用于所有血浆测量。利莫那班增强了 H-EVE 诱导的催产素(OT)分泌,并完全逆转了地塞米松对相同刺激的抑制作用。这些数据表明,糖皮质激素对 OT 释放的调节是由 CB(1) 受体介导的。尽管地塞米松不影响 H-EVE 诱导的血管加压素(AVP)分泌,但利莫那班的给药增强了对相同刺激的 AVP 释放,支持了 CB(1) 受体独立于糖皮质激素介导的信号调节 AVP 分泌的假说。地塞米松单独不影响 I-EVE 或 H-EVE 刺激的心房利钠肽(ANP)释放。然而,利莫那班预处理增强了 H-EVE 诱导的 ANP 分泌,提示 CB(1) 受体可能在调节心血管功能的外周因素的控制中发挥作用。利莫那班还逆转了地塞米松对 H-EVE 诱导的皮质酮分泌的抑制作用,进一步支持了 CB(1) 受体可能参与糖皮质激素对下丘脑-垂体-肾上腺轴活性的负反馈的假说。总之,本研究的结果表明,CB(1) 受体调节神经垂体激素分泌和系统因子,如皮质酮和 ANP,从而参与细胞外液和血浆渗透压变化的体内平衡反应。